miRCURY LNA miRNA Power Inhibitor (5)

For loss-of-function studies of specific mature microRNAs, LNA-enhanced antisense oligonucleotides from QIAGEN are widely used to silence individual miRNAs and characterize their downstream targets. The miRCURY LNA miRNA Power Inhibitor line delivers higher potency than standard LNA inhibitors, so functional knock-down is achieved at lower working concentrations in transfection-based assays. Tm-normalized Locked Nucleic Acid chemistry gives the inhibitors strong target affinity and nuclease resistance, including against low-abundance miRNAs that are otherwise difficult to suppress.

These Power Inhibitors are routinely applied for target validation, pathway dissection, and studies of miRNA involvement in oncology, neurobiology, immunology, and stem-cell biology. They transfect efficiently with standard lipid-mediated reagents and perform across many mammalian cell lines, primary cells, and 3D culture models. Common readouts include qPCR-based detection of de-repressed miRNA targets, luciferase reporter assays, Western blot confirmation of downstream protein changes, and phenotypic screens. The same chemistry supports in vivo applications following validated delivery protocols.

Each tube is supplied as 5 nmol of lyophilized inhibitor, sufficient for multiple transfection experiments across standard multi-well plate formats. The product ships at room temperature and should be reconstituted in nuclease-free water or TE buffer, typically to a 50 uM stock. Store the lyophilized vial at -20 °C, protected from light, and aliquot working stocks to limit freeze-thaw cycles. For research use only, this Power Inhibitor format from QIAGEN delivers reproducible, sequence-specific miRNA inhibition with minimal off-target effects when paired with scrambled or mismatched LNA controls.